<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body class="page">
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span><a href="/">&larr; Back to Home</a></span>
        <span class="date">2024-04-15</span>
        
        
        
          
        
        
        <span><a href="https://github.com/rainoffallingstar/daily-rss/edit/master/content/post/pubmed-ncbi-nlm-nih-gov-38620072-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240416181724-v-2-18-0-post9-e462414.md">Edit this page &rarr;</a></span>
        
        
      
      </div>
    </nav>

<div class="container">
<article>
<div class="article-meta">

  <div class="categories">
  
  </div>

  <h1><span class="title">Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial</span></h1>

  

  
  

</div>



<main>
<p>The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)-guided triple combination of acalabrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in 45 patients with relapsed/refractory CLL (one patient was excluded from the analysis due to a violation of exclusion criteria). MRD was measured by flow cytometry (FCM, undetectable MRD &lt;10-4) in peripheral blood (PB) and circulating tumor DNA (ctDNA) by digital droplet PCR (ddPCR) &hellip;</p>

<script>
var url = "https://pubmed.ncbi.nlm.nih.gov/38620072/?utm_source=curl\u0026utm_medium=rss\u0026utm_campaign=journals\u0026utm_content=7603509\u0026fc=None\u0026ff=20240416181724\u0026v=2.18.0.post9+e462414";
var strReg = "http|https";
var re = new RegExp(strReg);
setTimeout(function() { if(re.test(url)) {window.location.href = url} }, 10000);
</script>
</main>




<nav class="post-nav">
  <span class="nav-prev"><a href="/post/pubmed-ncbi-nlm-nih-gov-38620036-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240416181853-v-2-18-0-post9-/">&larr; Progression of herpesvirus infection remodels mitochondrial organization and metabolism</a></span>
  <span class="nav-next"><a href="/post/pubmed-ncbi-nlm-nih-gov-38620072-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240416181853-v-2-18-0-post9-/">Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial &rarr;</a></span>
</nav>




</article>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

